Chelation therapy uses binding agents (DMSA, DMPS, EDTA, ALA) to mobilise and excrete heavy metals. Agent selection depends on the metal involved. A pre-chelation workup, mineral repletion, and careful monitoring are non-negotiable for safety.

Heavy metals like mercury and lead can get stuck in your body and cause problems. Chelation therapy uses special medicines that grab those metals and help your kidneys flush them out — like a magnet pulling metal out of sand.

At a Glance

Question	Quick Answer
What is chelation?	A therapy using binding molecules (chelators) to mobilise and excrete heavy metals via urine or stool
Most common agents	DMSA (oral), DMPS (oral/IV), EDTA (IV/suppository), ALA (adjunct)
Primary target metals	Mercury · Lead · Arsenic · Cadmium · Nickel · Aluminum
Who needs it?	Patients with confirmed elevated body burden on provoked urine or RBC testing — not based on symptoms alone
Key risk	Mineral depletion (zinc, copper, magnesium) and redistribution of mobilised metals if done incorrectly
Monitoring required?	Yes — liver, kidney, CBC, and mineral panels before and during
Setting	Always under physician supervision; some protocols require IV infusion at a registered clinic

Heavy metal toxicity occupies an unusual space in medicine: universally acknowledged as real in acute poisoning, yet persistently controversial when it comes to chronic low-level exposure. Over two decades of integrative clinical practice, I have tested thousands of patients for heavy metal burden and treated hundreds with formal chelation protocols. The picture that emerges is nuanced — not every fatigued patient needs chelation, but a significant subset carry a metal burden that measurably drives their symptoms, and the right protocol, applied carefully, can produce remarkable clinical shifts.

This article covers the clinical framework I use: which chelating agents I choose and why, the pre-chelation workup I require before the first dose, the supporting regimen during active chelation, and the monitoring strategy that keeps the process safe.

What Heavy Metals Actually Do in the Body

Metals such as lead, mercury, arsenic, cadmium, and nickel share a destructive biochemical trick: they bind sulphur-containing groups on enzymes and structural proteins. Glutathione — the body’s master antioxidant and the backbone of phase-II detoxification — is a primary target. Deplete glutathione reserves or block the cysteine residues glutathione depends on, and you impair mitochondrial function, upregulate neuroinflammation, and compromise immune regulation simultaneously.

Chronic low-level exposure also displaces essential minerals from their receptor sites. Mercury displaces zinc at zinc-finger transcription factors. Lead competes with calcium at neuronal signalling sites, which is why low-level childhood lead exposure correlates strongly with neurodevelopmental deficits even when whole-blood lead is below historical “safe” thresholds. Cadmium accumulates in the kidney tubules and progressively degrades renal concentrating ability over years.

The pattern I see clinically is rarely a single metal — it is almost always a mixture, and the synergistic toxicity of two or three metals together tends to exceed the sum of their individual effects.

The Chelation Agents I Use — and When

Chelators are not interchangeable. Each has a distinct binding affinity profile, distribution volume, and excretion pathway. Using the wrong agent can mobilise a metal without providing sufficient binding capacity, risking redistribution into tissues — including the central nervous system — where it causes more harm than if it had stayed put.

DMSA (Dimercaptosuccinic Acid)

DMSA is an oral, water-soluble chelator with strong affinity for mercury, lead, and arsenic. Because it does not readily cross the blood-brain barrier in its free form, DMSA is my first-line agent for mercury that has not yet crossed into the CNS in significant quantity. It excrets primarily through the urine, so adequate kidney function is a prerequisite. I typically use 10 mg/kg every eight hours for three days on, eleven days off — the Cutler-informed pulse protocol — which allows mineral stores to partially recover between rounds and reduces the risk of rebound redistribution.

DMSA is generally well tolerated. The most common side effects are sulphur-like breath (the compound itself smells), mild GI upset, and transient rises in liver transaminases. I check LFTs after the first two rounds and then quarterly.

DMPS (Dimercaptopropane Sulfonate)

DMPS has a similar mechanism to DMSA but with higher water solubility, faster kinetics, and stronger affinity specifically for mercury — including inorganic mercury stored in the kidneys. Available both orally and intravenously, DMPS IV provides a significantly higher peak plasma concentration that mobilises deeper tissue stores more aggressively than oral DMSA alone.

I use IV DMPS for patients with high inorganic mercury burden documented on provoked urine, particularly when oral DMSA rounds have plateaued without achieving satisfactory reduction. The IV route requires careful slow infusion (over 30–60 minutes), with the patient monitored for hypotension and allergic reactions — rare but possible. Oral DMPS can be used on the same pulse schedule as oral DMSA.

DMPS is not approved by the FDA but is widely used in Germany, where it has been in clinical use for decades. Patients travelling to our clinic from North America often access IV DMPS here that is unavailable at home.

EDTA (Ethylenediaminetetraacetic Acid)

EDTA binds divalent and trivalent cations broadly — lead, cadmium, iron, and calcium among them. It does not bind mercury with clinically relevant affinity, so it is not the right choice for mercury-dominant patients. For lead, cadmium, and cardiovascular calcification burden, IV EDTA is, however, the best-studied chelation intervention available. The landmark TACT trial (Trial to Assess Chelation Therapy, JAMA 2013) demonstrated that IV EDTA reduced cardiovascular events by 18% in post-myocardial-infarction patients — a finding that shifted my practice considerably regarding cardiovascular patients with confirmed metal burden.

EDTA is also available as rectal suppositories, which provide a slower-release alternative for patients who cannot tolerate IV infusions or who are managing a gentler maintenance protocol. Suppository bioavailability is lower than IV, but for maintenance or mild burden this is clinically acceptable.

Because EDTA chelates calcium as well as lead, kidney function monitoring is especially important. I do not use EDTA in patients with GFR below 45 ml/min.

Alpha-Lipoic Acid (ALA) — The Critical Adjunct

ALA is not a primary chelator, but it is the only agent in common clinical use that crosses the blood-brain barrier with meaningful efficiency and has affinity for mercury in its reduced form. For patients with neurological symptoms dominated by mercury — cognitive fog, peripheral neuropathy, emotional lability — I add ALA to the protocol after at least several DMSA rounds have reduced the peripheral (non-CNS) body burden.

The critical rule with ALA is dose timing: it must be dosed every three to four hours around the clock during active rounds (including overnight), because its short half-life means that if ALA is present in the CNS without enough binding capacity, mobilised mercury can redistribute before being excreted. This discipline makes ALA rounds demanding for patients, but the neurological improvement I see when it is used correctly — after proper preparation — justifies the effort. For a comprehensive review of ALA’s mechanisms, neuropathy evidence base, and R-ALA versus racemic dosing, see our alpha-lipoic acid guide.

The Pre-Chelation Workup I Require

No chelation agent leaves the body before it has been mobilised into circulation first. Mobilisation is the dangerous window. If the patient’s detox pathways are already impaired — liver phase-II sluggish, glutathione depleted, kidney function marginal — mobilised metals circulate longer and have more opportunity to redeposit.

My pre-chelation checklist:

Laboratory baseline

Comprehensive metabolic panel (BMP + LFTs): kidney and liver must be functional
CBC with differential: chelation places oxidative stress on RBCs
Serum zinc, copper, magnesium, selenium: minerals that will be co-chelated and must be replete before starting
Whole-blood lead, urine arsenic/mercury (unprovoked): establishes the baseline without provocation artefact
Provoked urine heavy metal test (6-hour collection after DMSA or DMPS challenge dose): quantifies mobilisable body burden
Serum glutathione or urinary 8-OHdG as oxidative stress marker

Minimum pre-chelation mineral repletion period: 4 weeks I do not start chelation until zinc, magnesium, and selenium are in the upper half of their reference ranges. Zinc is co-chelated with DMSA and DMPS and drops measurably during rounds; starting replete provides a safety buffer. Selenium supports glutathione peroxidase activity, which is essential for handling the oxidative load that chelation generates.

Assess gut integrity Many chronically ill patients have significant intestinal permeability. If the gut barrier is compromised, orally administered chelators may partially bind metals in the gut lumen and then release them in a more permeable zone before excretion — a redistribution risk. I prioritise gut repair (see our protocols-gut-reset article) before initiating intensive chelation in patients with active gut symptoms.

Rule out active amalgam release If a patient still has amalgam fillings, I do not start chelation. Mercury vapour outgassing from fillings during chelation dramatically increases the incoming load while we are simultaneously trying to reduce body burden — it is like bailing a boat with the plughole still open. I coordinate with a biological dentist for safe amalgam removal (using rubber dam, high-volume evacuation, chunking technique) before any round of chelation.

Supporting the Body During Active Rounds

Chelation generates oxidative stress. The mobilised metals themselves are pro-oxidant, and the chelation process consumes glutathione — restoring these stores with IV glutathione therapy between rounds is a cornerstone of our protocol. Without support, patients feel dramatically worse during rounds — and some practitioners take this as a sign the protocol is working (“herxing”), when in reality it often signals insufficient support.

My standard support stack during chelation rounds:

Supplement	Dose	Purpose
Reduced glutathione (liposomal or IV)	500–1000 mg/day	Replaces depleted GSH; supports excretion
N-Acetyl Cysteine (NAC)	600 mg twice daily	GSH precursor; not on same days as chelators (competes)
Zinc picolinate	30–50 mg/day	Replaces co-chelated zinc
Magnesium glycinate	300–400 mg/day	Co-chelated; supports detox enzymes
Selenium (as selenomethionine)	200 mcg/day	Glutathione peroxidase cofactor
Milk thistle (silymarin 70–80%)	300 mg twice daily	Hepatoprotection
Activated charcoal (on chelation days)	1–2 g, timed away from chelators	Binds metals released into gut lumen via bile
Vitamin C (buffered)	2–4 g/day in divided doses	Antioxidant support; enhances urinary excretion

NAC is a special case: on active chelation days I withhold NAC because its free thiol group competes with DMSA/DMPS for metal binding, reducing chelator efficiency. I use it on the off-days instead to rebuild glutathione.

Monitoring During the Protocol

Chelation is a months-long process. I retest at defined intervals:

After rounds 2–3: Serum zinc, copper, magnesium, LFTs. Adjust mineral supplementation if needed.
After rounds 6–8: Repeat provoked urine heavy metals. Reduction should be measurable; if not, reassess agent selection.
Every 12 rounds (approximately 6 months): Full CBC, metabolic panel, mineral panel, and a clinical symptom review using a validated fatigue and cognitive questionnaire.
End of protocol: Full retest to confirm satisfactory reduction in mobilisable burden and document clinical outcomes.

I have learned to treat plateaus as diagnostic signals rather than failures. A patient whose provoked mercury consistently stops improving after initial reduction often has an ongoing source (residual amalgam debris, contaminated seafood intake, occupational exposure) or a methylation bottleneck limiting the conversion of inorganic to excretable forms. Re-examining the case — not simply adding more chelation — is the right response.

What Patients Should Realistically Expect

Chelation is slow, cumulative work. Most patients with moderate body burden complete 20–40 rounds before achieving satisfactory reduction, which translates to 12–24 months at the on/off pulse cadence. Patients who have carried a high burden for decades should not expect resolution in a few months.

Symptom improvement is not linear. Many patients feel transiently worse during the first two or three rounds as mobilisation begins — fatigue, mild headaches, altered sleep, and increased brain fog are common. By rounds four to six, most patients with genuine heavy metal-driven pathology begin noticing gradual improvements in energy, cognitive clarity, and pain. The improvements tend to be subtle at first and become more apparent in retrospect.

Patients who do not improve after six to eight rounds, or who worsen consistently without the expected transient nature, need a protocol reassessment. Not all fatigue and cognitive symptoms in chronically ill patients are metal-driven; continuing chelation in a patient whose primary driver is something else (MCAS, unaddressed Lyme co-infections, mould/CIRS) delays the treatment they actually need.

References

Lamas GA, Goertz C, Boineau R, et al. Effect of disodium EDTA chelation regimen on cardiovascular events in patients with previous myocardial infarction: the TACT randomized trial. JAMA. 2013;309(12):1241-1250. PMID: 23532240
Rogan WJ, Dietrich KN, Ware JH, et al. The effect of chelation therapy with succimer on neuropsychological development in children exposed to lead. N Engl J Med. 2001;344(19):1421-1426. PMID: 11346806
Aposhian HV, Maiorino RM, Rivera M, et al. Human studies with the chelating agents, DMPS and DMSA. J Toxicol Clin Toxicol. 1992;30(4):505-528. PMID: 1479147
Crinnion WJ. Environmental medicine, part 4: Pesticides — biologically persistent and ubiquitous toxins. Altern Med Rev. 2000;5(5):432-447. PMID: 11056414
Clarkson TW, Magos L. The toxicology of mercury and its chemical compounds. Crit Rev Toxicol. 2006;36(8):609-662. PMID: 17001700
Patrick L. Mercury toxicity and antioxidants: Part 1: Role of glutathione and alpha-lipoic acid in the treatment of mercury toxicity. Altern Med Rev. 2002;7(6):456-471. PMID: 12495372
Genuis SJ, Birkholz D, Rodushkin I, Beesoon S. Blood, urine, and sweat (BUS) study: monitoring and elimination of bioaccumulated toxic elements. Arch Environ Contam Toxicol. 2011;61(2):344-357. PMID: 21057782

Heavy Metal Chelation Therapy: A Physician's Clinical Protocol